H.R. 19 · 116th Congress
Lower Costs, More Cures Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
147 cosponsors · 147 R
111 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.
What it does: CRS summary · Introduced in House · Dec 9, 2019
Lower Costs, More Cures Act of 2019
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.
The bill generally
- limits payment amounts for drugs and biologics under Medicare medical services,
- reduces cost-sharing under the Medicare prescription drug benefit,
- modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
- revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
- establishes several reporting requirements for drug manufacturers with respect to drug prices.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Lower Costs, More Cures Act of 2019
Latest action (Dec 19, 2019): Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Policy area: Health · Origin: House · Introduced: Dec 9, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.